HCW Biologics regains Nasdaq bid price compliance, plans reverse split

HCW Biologics Inc. (Nasdaq: HCWB) announced that the Nasdaq Hearings Panel found the company regained compliance with Nasdaq Listing Rule 5550(a)(2), known as the Bid Price Rule, on June 29, 2026.

The panel's determination follows a decision letter dated May 29, 2026. The company is now subject to a mandatory monitoring period through June 17, 2027.

To maintain long-term compliance with the Bid Price Rule, the Miramar, Fla.-based clinical-stage biopharmaceutical company said it will execute a one-for-six reverse stock split on June 30, 2026.

The company stated it is now compliant with all continued listing rules for Nasdaq.

You May Also Be Interested In

• Corning (GLW) files for up to $2B offering of common shares
• Peraso CFO James Sullivan resigns effective October 2026
• Natuzzi appeals NYSE delisting, converts €5M in loans to equity